Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 59 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
IMMO-PHARM from Etterbeek, company number BE0726954523, closed financial year 2025 with a result of € 16,580 after tax. For that financial year IMMO-PHARM recorded a gross margin of € 37,985 and equity of € 102,580. Compared with financial year 2024, the result moved from € 6,715 to € 16,580. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 29, 2026.
€ 102,580
▲ € 116,580 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 16,580
▲ 147% vs 2024
Profit after tax over the fiscal year.
€ 11,530
▲ € 9,202 vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -27,420.
Debts at end 2025
€ 381,507
▼ 5% vs 2024
€ 26,415 is repaid this year. At this pace the long-term loan is gone in ≈ 14 years.
€ 6,890
▼ 32% vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 30,404 | € 34,905 | € 24,868 | € 37,985 | ▲ 53% |
| Profit after taxes | € 11,387 | € 16,313 | € 6,715 | € 16,580 | ▲ 147% |
| Equity | € -37,027 | € -20,715 | € -14,000 | € 102,580 | ▲ € 116,580 |
| Total debts | € 454,664 | € 433,647 | € 414,195 | € 395,665 | ▼ 4% |
| Cash | € 2,489 | € 6,986 | € 2,327 | € 11,530 | ▲ € 9,202 |
| Land & buildings | € 409,095 | € 398,869 | € 388,642 | € 474,716 | ▲ 22% |
| Retained profit | € -67,027 | € -50,715 | € -44,000 | € -27,420 | ▲ € 16,580 |
| Bank debt | € 449,996 | € 426,938 | € 403,440 | € 381,507 | ▼ 5% |
| Balance sheet total | € 417,636 | € 412,932 | € 400,196 | € 498,245 | ▲ 25% |
Key figures of IMMO-PHARM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to IMMO-PHARM?
What happened at IMMO-PHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 16,580 (▲ 147% vs 2024). Source: NBB ↗
- CHRIQTOPHE GUYOT became a director. NBB
- New establishment in Etterbeek. KBO
- Start of the company according to the CBE. KBO
In short
From € 11,387 profit in 2022 to € 16,580 profit in 2025.
Best year ever: 2025, with € 16,580 profit.
Management
Behind IMMO-PHARM is CHRIQTOPHE GUYOT.
Directors
According to the 2025 annual accounts
CHRIQTOPHE GUYOT
Director
since 2022
Establishments
Establishment units
Physical locations of this company
Sint-Pietersplein 29 box 1
1040 Etterbeek
Sint-Pietersplein 29 box 4
1040 Etterbeek
Active since 21 May 2019
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
All companies at this address →ASSOCIATION DES COPROPRIETAIRES DE L'IMMEUBLE SIS à 1040 ETTERBEEK, PLACE SAINT-PIERRE 29
MY EXPRESS
€ 2.1 million revenue · 2025
Kesan Food
MEDITRINE
€ 145,949 gross margin · 2025
BLUE ADVICE & SERVICES
+1 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0726.954.523
- VAT number
- BE 0726.954.523
- Registered office
- Sint-Pietersplein 29 bus 1, 1040 Etterbeek
- Names & denominations
- IMMO-PHARM
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 21 May 2019
- Peppol
- Active · Active since 9 Oct 2025
- Contact
- [email protected] +32496877053